As the expiration of patents for blockbuster biopharmaceuticals approaches, competition in the biosimilar market is intensifying. With over 300 trillion won in market opportunities, many products still represent 'gaps' where biosimilar development has yet to occur. Global companies are accelerating their efforts to secure candidate substances, while firms from China and India are rapidly obtaining approvals in the U.S. and Europe.
According to global pharmaceutical market research firm IQVIA, 118 biopharmaceutical patents are set to expire in the U.S. between 2025 and 2034. This presents an estimated market opportunity of approximately $234 billion (about 314 trillion won). However, as of June 2024, only 12 biosimilars (about 10%) are currently in development, leaving 106 in a 'biosimilar gap' with no competitors.
In response, global biotech companies are moving to fill these gaps. Germany's Fresenius has signed an exclusive development agreement with China's Wuxi Biologics for up to 37 biosimilar candidates. The company plans to expand its current portfolio of 29 to a maximum of 66 within the next decade. In September, Fresenius acquired the remaining 45% stake in Spain's Mabxience, making it a wholly-owned subsidiary. Swiss firm Sandoz has also launched its 'Bio100' strategy, aiming to grow its current portfolio of 13 to over 100 by 2040.
Regulatory barriers are also being lowered. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are adjusting their regulations to potentially waive comparative efficacy clinical trials for some products if analytical characterization and pharmacokinetic similarity studies are sufficient. This reduction in development costs and timelines is expected to accelerate market entry for new players.
In terms of approval performance, China and India are leading in the Asian market. According to a recent report by the Korea Bio Association, of the nine biosimilars approved by the FDA from January to September this year, seven were from the Asia-Pacific region. Among the 12 approved by the European Commission by the end of July, 10 were also from Asia, with none from South Korea. All 17 approvals were for products from India (nine) and China (eight).
India has increased approvals for established products such as the ophthalmic treatment Ranibizumab and the bone disease treatment Denosumab. China secured four approvals in new areas, including the first U.S. biosimilar for Golimumab and the first European biosimilar for Pertuzumab. Companies like Henlius Biotech from China and Biocon from India are also planning to expand their market presence.
South Korean companies are currently taking a breather this year. Celltrion and Samsung Bioepis received approvals for their biosimilars of Ustekinumab and Denosumab from 2024 to last year. Celltrion has also secured approvals for its biosimilars of Tocilizumab and Omadacycline. Following a series of approvals, these companies have focused on selling existing products this year.
BioPharma APAC has noted that Celltrion and Samsung Bioepis have played a pioneering role among Asia-Pacific biosimilar companies by selling products manufactured in Asia through partners with established Western distribution networks.
The approved products are translating into tangible results. Samsung Bioepis reported in its third-quarter earnings announcement that the global sales expansion of its Soliris biosimilar SB12 (ingredient name Eculizumab) and Stelara biosimilar SB17 (ingredient name Ustekinumab) has driven growth. Additionally, Celltrion's Omadacycline biosimilar Omniclo has seen cumulative sales of 320.5 billion won in the third quarter, increasing more than sixfold over the past year.
Industry insiders predict that the biosimilar of the immuno-oncology drug Keytruda, for which both companies have applied for approval, will serve as a litmus test for the resurgence of South Korean biosimilars.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.